Targeting low NECTIN4-expressing tumor cells is particularly relevant for UC, given a recent study showing that membranous surface expression of NECTIN4 decreases with progression to metastatic disease and that low NECTIN4 expression in metastatic biopsies is associated with impaired responses and outcomes with EV treatment47. Here, NECTIN4 is linked to metastatic neoplasm.